RetroSense Therapeutics

About:

RetroSense Therapeutics is a biotechnology company developing gene therapy for vision restoration.

Top Investors: Michigan Economic Development Corporation, Ann Arbor SPARK, Tech Coast Angels, ExSight Ventures, Santen Pharmaceutical

Description:

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

Total Funding Amount:

$17M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Ann Arbor, Michigan, United States

Founded Date:

2009-01-01

Contact Email:

info(AT)retro-sense.com

Founders:

Sean Ainsworth

Number of Employees:

1-10

Last Funding Date:

2015-11-12

IPO Status:

Private

Industries: